Loading...
Market
What will BridgeBio's stock price ($BBIO) be by December 31, 2024?
3
Resolution / Starting Odds
Below $30 • 25%
$30-$40 • 25%
$40-$50 • 25%
Above $50 • 25%
Stock market data from financial news sources like Bloomberg or Yahoo Finance
Story
BridgeBio's Infigratinib Receives FDA Breakthrough Therapy Designation, Stock Surges 64.2%
Sep 17, 2024, 11:32 AM
BridgeBio Pharma announced that its investigational therapeutic, infigratinib, has been awarded Breakthrough Therapy Designation by the FDA. This marks the first time such a designation has been given to a treatment for achondroplasia. The designation is expected to expedite the development and review of infigratinib, which is being developed as an oral treatment for children with achondroplasia. Following this announcement, BridgeBio's stock ($BBIO) surged by 64.2%.
View original story
Similar markets
Above $25 • 25%
Between $20 and $25 • 25%
Between $15 and $20 • 25%
Below $15 • 25%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Remain within 10% of current price • 25%
Decrease by more than 10% • 25%
Below $100 • 25%
$100 - $150 • 25%
$150 - $200 • 25%
Above $200 • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Higher than competitors • 25%
On par with competitors • 25%
Lower than competitors • 25%
Significantly lower than competitors • 25%
Below $0.50 • 25%
$0.50 - $0.99 • 25%
$1.00 - $1.49 • 25%
$1.50 and above • 25%
Below $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
Above $3 billion • 25%